|
|
|
CLRBW - Cellectar Biosciences, Inc.
Cellectar
Biosciences, Inc. (CLRBW) is a clinical-stage biopharmaceutical
company that is focused on the development of targeted cancer
therapies. The company's proprietary phospholipid drug conjugate (PDC)
platform technology allows for the delivery of therapeutic agents
directly to cancer cells, while minimizing toxicity to healthy cells.
Cellectar Biosciences' lead drug candidate is CLR 131, a PDC-based
radiotherapeutic that is being developed for the treatment of a
variety of cancers, including multiple myeloma and certain types of
lymphoma. The drug works by delivering a radioactive payload directly
to cancer cells, while sparing healthy cells from radiation damage.
In addition to CLR 131, Cellectar Biosciences is also developing a
pipeline of other PDC-based therapies for the treatment of cancer. The
company's pipeline includes CLR 125, a PDC-based imaging agent for use
in cancer detection, and CLR 1900, a PDC-based therapeutic that is
being developed for the treatment of pediatric cancers.
Cellectar Biosciences was founded in 2002 and is headquartered in
Florham Park, New Jersey. The company has a small team of employees
and collaborates with academic and industry partners to advance its
drug development programs. As of 2021, the company is focused on
advancing CLR 131 through clinical trials and seeking regulatory
approval for the drug. Cellectar Biosciences faces significant
competition from other companies developing cancer therapies,
particularly in the areas of radiotherapeutics and targeted
|
|
|
|
|
